1. Home
  2. FPI vs MNPR Comparison

FPI vs MNPR Comparison

Compare FPI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Farmland Partners Inc.

FPI

Farmland Partners Inc.

HOLD

Current Price

$9.71

Market Cap

503.5M

Sector

Real Estate

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$107.58

Market Cap

587.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FPI
MNPR
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
587.4M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
FPI
MNPR
Price
$9.71
$107.58
Analyst Decision
Hold
Strong Buy
Analyst Count
1
11
Target Price
N/A
$107.00
AVG Volume (30 Days)
385.2K
213.9K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
3.14%
N/A
EPS Growth
N/A
54.99
EPS
0.01
N/A
Revenue
$52,178,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$962.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.37
$29.18
52 Week High
$13.23
$116.64

Technical Indicators

Market Signals
Indicator
FPI
MNPR
Relative Strength Index (RSI) 49.24 61.46
Support Level $9.45 $52.92
Resistance Level $9.92 $112.57
Average True Range (ATR) 0.16 8.45
MACD 0.03 -1.06
Stochastic Oscillator 55.87 53.84

Price Performance

Historical Comparison
FPI
MNPR

About FPI Farmland Partners Inc.

Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Share on Social Networks: